한글목차

MAXIGESIC IV(파라세타몰+이부프로펜)는 특허를 받은 새로운 듀얼 모드 비오피오이드 통증 치료제로, 미국에서 아세트아미노펜으로 알려진 파라세타몰 1,000mg과 이부프로펜 300mg의 독특한 조합으로 경구용 진통제 약물 사용이 제한된 환자의 수술 후 병원에서 사용되는 수액용입니다. 이 특별한 조합은 파라세타몰과 이부프로펜의 하루 최대 용량을 허용하며, 파라세타몰이 페닐에프린에 작용하도록 설계되어 페닐에프린의 혈중 이동 수준을 실질적으로 두 배로 증가시킵니다.

MAXIGESIC은 열을 내리고 두통, 편두통, 긴장성 두통, 부비동통, 치통, 치과 치료, 요통, 인후통, 관절염, 테니스 엘보, 생리통, 근육통, 류머티즘성 통증, 감기 및 독감에 따른 통증을 일시적으로 완화합니다. 이 의약품은 파라세타몰과 이부프로펜의 독특한 조합으로 특허를 받았으며 다양한 통증 증상을 빠르고 효과적으로 완화하는 것으로 입증되었습니다.

미국의 MAXIGESIC IV 시장에 대해 조사했으며, 시장 개요와 함께 2023-2032년까지의 매출 예측 데이터, 경쟁 상황, 국가별 동향 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 급성 통증에 대한 MAXIGESIC IV 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제상 마일스톤
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 상황(출시된 치료법)

제4장 경쟁 상황(후기 단계 새로운 치료법)

제5장 MAXIGESIC IV 시장 평가

• 급성 통증의 MAXIGESIC IV 시장 전망
• 미국의 분석

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

• 참고문헌
• 보고서 조사 방법

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 보고서 구입 옵션

영문목차

"MAXIGESIC IV Drug Insight and Market Forecast - 2032" report provides comprehensive insights about MAXIGESIC IV for acute pain in the United States. A detailed picture of the MAXIGESIC IV for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the MAXIGESIC IV for acute pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MAXIGESIC IV market forecast analysis for acute pain in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute pain.

Drug Summary:

MAXIGESIC IV (paracetamol + ibuprofen), a novel, patented, dual mode-of-action non-opioid pain treatment, is a unique combination of paracetamol (known as acetaminophen in the US) 1,000 mg + ibuprofen 300 mg solution for infusion for use postoperatively in hospitals for patients for whom the use of oral analgesics is limited. This specific combination is designed to allow the maximum daily dose of paracetamol and ibuprofen and to allow for the effect of paracetamol on phenylephrine when combined, the level of phenylephrine crossing into the bloodstream effectively doubles.

MAXIGESIC reduces fever and temporarily relieves pain associated with headaches, migraines, tension headaches, sinus pain, toothache, dental procedures, backache, sore throat, arthritis, tennis elbow, period pain, muscular pain, rheumatic pain, aches and pains associated with colds and flu. The drug is a unique patented combination of paracetamol and ibuprofen, proven to provide fast and effective relief from a wide range of pain symptoms.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the MAXIGESIC IV description, mechanism of action, dosage and administration, research and development activities in acute pain.
• Elaborated details on MAXIGESIC IV regulatory milestones and other development activities have been provided in this report.
• The report also highlights the MAXIGESIC IV research and development activities in acute pain across the United States.
• The report also covers the patents information with expiry timeline around MAXIGESIC IV.
• The report contains forecasted sales of MAXIGESIC IV for acute pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for acute pain.
• The report also features the SWOT analysis with analyst views for MAXIGESIC IV in acute pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MAXIGESIC IV Analytical Perspective by DelveInsight

In-depth MAXIGESIC IV Market Assessment

This report provides a detailed market assessment of MAXIGESIC IV for acute pain in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

MAXIGESIC IV Clinical Assessment

The report provides the clinical trials information of MAXIGESIC IV for acute pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for acute pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MAXIGESIC IV dominance.
• Other emerging products for acute pain are expected to give tough market competition to MAXIGESIC IV and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MAXIGESIC IV in acute pain.
• Our in-depth analysis of the forecasted sales data of MAXIGESIC IV from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MAXIGESIC IV in acute pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of MAXIGESIC IV?
• What is the clinical trial status of the study related to MAXIGESIC IV in acute pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MAXIGESIC IV development?
• What are the key designations that have been granted to MAXIGESIC IV for acute pain?
• What is the forecasted market scenario of MAXIGESIC IV for acute pain?
• What are the forecasted sales of MAXIGESIC IV in the United States?
• What are the other emerging products available and how are these giving competition to MAXIGESIC IV for acute pain?
• Which are the late-stage emerging therapies under development for the treatment of acute pain?

Table of Contents

1. Report Introduction

2. MAXIGESIC IV Overview in Acute pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. MAXIGESIC IV Market Assessment

• 5.1. Market Outlook of MAXIGESIC IV in Acute pain
• 5.2. The United States Analysis
  • 5.2.1. Market Size of MAXIGESIC IV in the United States for Acute pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options